| Company Name: |
Hangzhou Peptidego Biotech Co.,Ltd.
|
| Tel: |
0571-87213919 |
| Email: |
Eric@peptidego.com |
| Products Intro: |
Product Name:TRP-601
CAS:1094569-02-4
Purity:95% or 98% HPLC Package:1mg；5mg；10mg；50mg；100mg,1g or according to customer's detail requirement.
|
| Company Name: |
Hangzhou Sinoda Pharmaceutical Technology Co. LTD
|
| Tel: |
0571-87213919 17306812703 |
| Email: |
3007955328@qq.com |
| Products Intro: |
Product Name:TRP-601
CAS:1094569-02-4
Purity:95% or 98% HPLC Package:1mg；5mg；10mg；50mg；100mg,1g or according to customer's detail requirement.
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:TRP-601
CAS:1094569-02-4
Package:25mg/RMB 10600
|
|
| | L-Alaninamide, N-(2-quinolinylcarbonyl)-L-valyl-L-α-aspartyl-L-valyl-N-[3-(2,6-difluorophenoxy)-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-, methyl ester Basic information |
| | L-Alaninamide, N-(2-quinolinylcarbonyl)-L-valyl-L-α-aspartyl-L-valyl-N-[3-(2,6-difluorophenoxy)-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-, methyl ester Chemical Properties |
| Boiling point | 1108.5±65.0 °C(Predicted) | | density | 1.283±0.06 g/cm3(Predicted) | | pka | 11.17±0.46(Predicted) |
| | L-Alaninamide, N-(2-quinolinylcarbonyl)-L-valyl-L-α-aspartyl-L-valyl-N-[3-(2,6-difluorophenoxy)-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-, methyl ester Usage And Synthesis |
| Uses | TRP-601 is a caspase inhibitor. TRP-601 reversed the increased expression of active caspase-2, the activation of endogenous apoptotic pathway and the up-regulation of key protein triggered by hyperoxia[1]. | | in vivo | TRP-601 (1 mg/kg, Intraperitoneal injection, single dose) reduces hyperoxia-induced caspase activation in rats, attenuates neuronal cell death in the developing brain in rats and inhibits intrinsic apoptotic signaling[1]. | Animal Model: | Wistar rats [1] | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Ameliorated the increase of caspase-3 activity and reduced protein expression of processed caspase-2 and enzymatic activity.
Significantly reduced neuronal cell death and did not influence levels of physiological apoptosis.
Decreased Apaf-1 protein expression to control levels.
Increased mRNA expression of Bcl-2. |
| | IC 50 | Caspase-2; Caspase 3; Bcl-2 | | References | [1] M Sifringer, et al. Prevention of neonatal oxygen-induced brain damage by reduction of intrinsic apoptosis. Cell Death Dis. 2012 Jan 12;3(1):e250. DOI:10.1038/cddis.2011.133
[2] Sifringer M, et al. Prevention of neonatal oxygen-induced brain damage by reduction of intrinsic apoptosis [J]. Cell death & disease, 2012, 3(1): e250-e250. |
| | L-Alaninamide, N-(2-quinolinylcarbonyl)-L-valyl-L-α-aspartyl-L-valyl-N-[3-(2,6-difluorophenoxy)-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-, methyl ester Preparation Products And Raw materials |
|